United Therapeutics (NASDAQ:UTHR) CEO Sells $5,072,050.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $533.90, for a total transaction of $5,072,050.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $21,629,890.70. This represents a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $527.00 on Friday. The company has a market cap of $23.10 billion, a price-to-earnings ratio of 18.89, a P/E/G ratio of 1.91 and a beta of 0.84. The stock’s fifty day moving average price is $489.57 and its two-hundred day moving average price is $466.41. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $548.12.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The business’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period last year, the firm earned $6.19 EPS. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Analysts have largely raised targets and maintained buy/outperform views, supporting valuation — multiple firms (UBS, RBC, TD Cowen, Cantor Fitzgerald, Jefferies) recently lifted targets or reiterated buy ratings, keeping the consensus at a moderate buy. MarketBeat UTHR coverage
• Positive Sentiment: Solid recent quarterly results: UTHR reported an EPS beat (reported $7.70 vs. $6.78 consensus) with healthy margins, which supports earnings momentum despite a modest revenue miss. Earnings summary
• Neutral Sentiment: Sector comparison pieces (e.g., CPRX vs UTHR) are circulating; these may attract relative‑value buyers but are not company‑specific catalysts. Zacks comparison
• Neutral Sentiment: Institutional ownership remains very high (~94%) with some recent modest position changes by funds — this can mute volatility from retail flows but also concentrates sell pressure when insiders sell. MarketBeat institutional note
• Negative Sentiment: CEO Martine Rothblatt sold a large block in mid‑March — roughly 9,500 shares at about $533–$538/share (≈$5.1M), with filings showing a substantial reduction in her direct stake; such headline insider selling typically pressures the stock. SEC filing
• Negative Sentiment: EVP Paul A. Mahon sold 8,300 shares at an average ~$529.95 (≈$4.4M) on March 19, further adding to sell‑side pressure from insiders. SEC filing

Analysts Set New Price Targets

UTHR has been the subject of several recent research reports. TD Cowen boosted their price objective on United Therapeutics from $525.00 to $575.00 and gave the stock a “buy” rating in a report on Wednesday, February 25th. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, February 26th. Finally, UBS Group raised their price objective on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $548.09.

Hedge Funds Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. AXQ Capital LP increased its position in shares of United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after buying an additional 3,235 shares in the last quarter. AE Wealth Management LLC lifted its holdings in United Therapeutics by 396.3% during the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company’s stock worth $1,798,000 after acquiring an additional 3,424 shares in the last quarter. Great Lakes Advisors LLC grew its stake in United Therapeutics by 194.7% in the third quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company’s stock valued at $1,888,000 after acquiring an additional 2,975 shares during the period. Optimize Financial Inc acquired a new stake in shares of United Therapeutics during the third quarter worth about $444,000. Finally, Simplify Asset Management Inc. bought a new position in shares of United Therapeutics during the 3rd quarter valued at about $8,351,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.